DEXCOM INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Insulet (PODD) reported Q2 revenue of $801.7M, up 23.5% YoY, beating estimates by 1.9% but missing next quarter's guidance. Peers iRhythm (IRTC), ResMed (RMD), and DexCom (DXCM) also reported earnings, with mixed market reactions. PODD is down 11.6% since reporting, while DXCM is up 20.6%.
iRhythm (IRTC) reported Q2 revenue of $224.2M, up 20.1% YoY, beating estimates. ResMed (RMD) reported $1.46B in revenue, up 8.6% YoY, in line with expectations. Insulet (PODD) reported $801.7M in revenue, up 23.5% YoY, beating estimates but missing guidance. IRTC stock is down 4.4%, RMD up 3.4%, and PODD down 11.6% since reporting.
Abbott ABT and DexCom DXCM are key players in the continuous glucose monitoring (CGM) market. Abbott's Q2 2026 CGM sales reached $2B, up 9.5%, with new product innovations. DexCom's Q2 2026 revenue rose 13% YoY to $1.31B. The global CGM market is projected to grow to $41.4B by 2033. DXCM shares rose 19.9% in the past year, while ABT shares fell 11.5%.
Over the past 7 days, alphai's AI scored 1 news story mentioning DXCM (DEXCOM INC). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent DXCM coverage spans earnings, market movers and financial news.
In the last 30 days, DXCM insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($2.9M). The most active reporter was SAYER KEVIN R, Executive Chair, with 3 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Revenue beat with strong price rally despite weak guidance.
iRhythm (IRTC) reported Q2 revenue of $224.2M, up 20.1% YoY, beating estimates. ResMed (RMD) reported $1.46B in revenue, up 8.6% YoY, in line with expectations. Insulet (PODD) reported $801.7M in revenue, up 23.5% YoY, beating estimates but missing guidance. IRTC stock is down 4.4%, RMD up 3.4%, and PODD down 11.6% since reporting.
Strong revenue growth may support price appreciation, but the story is a side‑by‑side comparison without a direct catalyst.
Insider sale may signal reduced confidence, creating short‑term downside pressure.
Dexcom and Health2Sync have partnered to enhance diabetes care in Australia and Singapore. Health2Sync's platform supports 1.7 million users, while Dexcom provides glucose monitoring tech. The collaboration aims to expand digital health solutions in the Asia-Pacific region.
alphai scores every news story that mentions DXCM with an AI model for sentiment and relevance, and aggregates insider trades from DEXCOM INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Insulet (PODD) reported Q2 revenue of $801.7M, up 23.5% YoY, beating estimates by 1.9% but missing next quarter's guidance. Peers iRhythm (IRTC), ResMed (RMD), and DexCom (DXCM) also reported earnings, with mixed market reactions. PODD is down 11.6% since reporting, while DXCM is up 20.6%.
3 min readiRhythm (IRTC) reported Q2 revenue of $224.2M, up 20.1% YoY, beating estimates. ResMed (RMD) reported $1.46B in revenue, up 8.6% YoY, in line with expectations. Insulet (PODD) reported $801.7M in revenue, up 23.5% YoY, beating estimates but missing guidance. IRTC stock is down 4.4%, RMD up 3.4%, and PODD down 11.6% since reporting.
2 min readAbbott ABT and DexCom DXCM are key players in the continuous glucose monitoring (CGM) market. Abbott's Q2 2026 CGM sales reached $2B, up 9.5%, with new product innovations. DexCom's Q2 2026 revenue rose 13% YoY to $1.31B. The global CGM market is projected to grow to $41.4B by 2033. DXCM shares rose 19.9% in the past year, while ABT shares fell 11.5%.
3 min readSAYER KEVIN R (Executive Chair) sold 26,756 shares of DEXCOM INC (DXCM) at an average of $90.01 ($89.71–$91.41, $2.41M total) across 3 trades on 2026-08-20 under a Rule 10b5-1 trading plan.
1 min readDexcom and Health2Sync have partnered to enhance diabetes care in Australia and Singapore. Health2Sync's platform supports 1.7 million users, while Dexcom provides glucose monitoring tech. The collaboration aims to expand digital health solutions in the Asia-Pacific region.
2 min readDexCom Inc (DXCM) stock reached a 52-week high of $92.01, with a 36% year-to-date return. The company reported Q2 revenue of $1.308B, up 13% YoY, and raised its financial guidance. Analysts increased price targets, with Piper Sandler setting a $95 target. DexCom's inclusion in the FDA's TEMPO program and a perfect Piotroski Score of 9 indicate strong financial health.
2 min readDexCom reported Q2 2026 revenue of $1.31B, up 13.1% YoY, and EPS of $0.70, beating estimates. Silvant Capital bought a $5.4M stake, while insiders sold shares. Analysts maintain 'buy' ratings with targets up to $93. The stock trades near its 12-month high.
2 min readBiotech and healthcare stocks hit 52-week highs on Aug. 14, 2026 after quarterly results or acquisition news. Eton Pharmaceuticals (ETON) rose over 44% to $59.79; Q2 net product sales grew 99% YoY and profit was $11.6M. DexCom (DXCM) reached $91.96; Q2 revenue $1.31B (+13%) and 2026 revenue guidance $5.18B-$5.25B. Oruka (ORKA) touched $111.37; AtaiBeckley (ATAI) $7.28 after an Eli Lilly (LLY) deal potentially worth $3.8B. Concentra (CON) hit $35.52; Q2 revenue $606M (+10%) and profit $67M.
4 min readDexCom (DXCM) designs continuous glucose monitoring systems. The stock lagged the S&P 500 and XLV over 52 weeks but gained 37.2% YTD. After Q2 2026 results on Jul. 30, adjusted EPS was $0.70 and revenue $1.31B, up 13% YoY, beating estimates. DexCom raised 2026 revenue guidance to $5.18B-$5.25B. Canaccord lifted its price target to $90; mean target $92.48.
4 min readDexCom (DXCM) shares are up 34.8% YTD in 2026 after a 14.7% drop in 2025, outperforming the industry and the S&P 500. In Q2, revenue rose 13% YoY and organic growth was 12%. U.S. revenue grew 11% and international 19%. Drivers cited include CGM expansion in non-insulin Type 2 diabetes and G7 15 Day adoption, which improved gross margin by about 400 bps.
6 min read
%252FDexcom%252520headquarters%252520building%252520By%252520MichaelVi.jpeg&w=3840&q=75)
